睑板腺癌中MMP-2的表达及其临床意义

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (5): 557-561.

睑板腺癌中MMP-2的表达及其临床意义

徐晓芳, 张蕾蕾, 贾仁兵, 周一雄, 宋欣, 范先群

上海交通大学医学院附属第九人民医院眼科,上海 200011

收稿日期:2015-01-13 修回日期:2015-05-07 发布日期:2015-06-11
通讯作者: 范先群,男,博士,主任医师,教授,研究方向:眼眶病眼肿瘤的综合治疗。Tel: 021-23271699-5586 E-mail: fanxq@sh163.net
作者简介:徐晓芳,女,博士,主治医师,研究方向:眼肿瘤的基因治疗。Tel: 13166087278 E-mail: xuxu0139@hotmail.com
基金资助:
上海市自然科学基金(12ZR1417300)

Expression and clinical significant of matrix metalloproteinase-2 in sebaceous carcinoma

XU Xiao-fang, ZHANG Lei-lei, JIA Ren-bing, ZHOU Yi-xiong, SONG Xin, FAN Xian-qun

Department of Ophthalmology, Sanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2015-01-13 Revised:2015-05-07 Published:2015-06-11

摘要/Abstract

摘要： 目的: 探讨基质金属蛋白酶-2(matrix metallop roteinase-2,MMP-2)在睑板腺囊肿和睑板腺癌组织中的表达差异及其与睑板腺癌临床病理特征的关系和临床意义。方法: 采用免疫组化SP法检测睑板腺囊肿和睑板腺癌组织中MMP-2、血管内皮生长因子(VEGF)的表达情况,以CD34标记检测肿瘤内的微血管密度(microvessel density, MVD),分析MMP-2与临床病理因素、VEGF、MVD的关系。结果: MMP-2在睑板腺癌组织中阳性表达率高于睑板腺囊肿(56% vs 20%),差异具有统计学意义(P﹤0.05),而VEGF表达在睑板腺癌和睑板腺囊肿中差别无统计学意义;MMP-2蛋白表达与肿瘤复发和局部浸润有关 (P﹤0.05),与患者年龄、组织学分级、病理类型和病程无关 (P﹥0.05)。MMP-2阳性的肿瘤组织内MVD明显高于MMP-2阴性肿瘤(P﹤0.05),VEGF的表达与MMP-2无相关性(r=-0.049,P=0.748)。结论: MMP-2在睑板腺癌中高表达,可能通过非VEFG依赖途径促进肿瘤的血管生成,进而参与肿瘤浸润和复发。

关键词: 基质金属蛋白酶-2, 微血管密度, 睑板腺癌, 血管内皮生长因子

Abstract: AIM: To investigate the differential expression of MMP-2 between chalazion and sebaceous carcinoma tissues and explore the association of expression of MMP-2 with clinical pathological features and its clinical significance.METHODS: The expression of MMP-2 and VEGF in chalazion (20 cases) and sebaceous carcinoma tissues (50 cases) were detected using immunohistochemical method of SP.The microvessel density (MVD) was calculated by CD34 immunostaining in the tumor.The relationship between MMP-2 and clinicopathological characteristics, VEGF and MVD were analyzed.RESULTS: The positive expression rates of MMP-2(56%) in sebaceous carcinoma tissues were higher when compared with chalazion tissues(20%), the difference was statistically significant (P<0.05),but there was no difference in the expression of VEGF between sebaceous carcinoma and chalazion tissues.The expression of MMP-2 was positively correlated with recurrence and local infiltration in sebaceous carcinoma (P<0.05), while there was no significant association between expression of MMP-2 and clinical characteristics including age, histological grade, pathological type and duration of unrelated (P>0.05).Though MVD in MMP-2-positive tumors was higher than that in MMP-2-negative tumors (P<0.05), the expression of VEGF was not correlated with MMP-2 (r=-0.049,P=0.748).CONCLUSION: MMP-2 was over-expressed in sebaceous carcinoma tissues and may be involved in the progress of invasion and recurrence in sebaceous carcinoma via a VEFG-independent way to promote tumor angiogenesis.

Key words: metalloproteinase 2, microvessel density, sebaceous carcinoma, vascular endothelial growth factor

中图分类号:

R246.8

徐晓芳, 张蕾蕾, 贾仁兵, 周一雄, 宋欣, 范先群. 睑板腺癌中MMP-2的表达及其临床意义[J]. 中国临床药理学与治疗学, 2015, 20(5): 557-561.

XU Xiao-fang, ZHANG Lei-lei, JIA Ren-bing, ZHOU Yi-xiong, SONG Xin, FAN Xian-qun. Expression and clinical significant of matrix metalloproteinase-2 in sebaceous carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 557-561.

参考文献

[1] Kale SM, Patil SB, Khare N, et al. Clinicopathological analysis of eyelid malignancies--a review of 85 cases [J]. Indian J Plast Surg, 2012, 45(1):22-28.
[2] Xu XL, Li B, Sun XL, et al. Eyelid neoplasms in the Beijing Tongren eye centre between 1997 and 2006 [J]. Ophthalmic Surg Lasers Imaging, 2008, 39 (5):367-372.
[3] Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases [J]. Curr Opin Cell Biol, 2004, 16(5):558-564.
[4] Luo J, Zha S, Gage WR, et al. Alpha--methylacyl-CoA Racemase: a new molecular marker for prostate cancer [J]. Cancer Res, 2002, 62(8):2220-2226.
[5] Mumane MJ, Cai J, Shuja S, et al. Active MMP-2 effectively identifies the presence of colorectal cancer [J]. Int J Cancer, 2009, 125(12):2893-2902.
[6] Langers AM, Verspaget HW, Hawinkels LJ, et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients [J]. Br J Cancer, 2012, 106 (9):1495-1498.
[7] Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma [J]. Hum Pathol, 2008, 39 (3): 377-385.
[8] Liu SC, Yang SF, Yeh KT, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer [J]. Clin Chim Acta , 2006, 371(1/2): 92-96.
[9] Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma [J]. Br J Cancer, 2003, 89(7): 1270-1275.
[10]Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis [J]. Cell Cycle, 2009, 8(5):683-688.
[11]Shapiro S, Khodalev O, Bitterman H, et al. Different activation forms of MMP-2 oppositely affect the fate of endothelial cells [J]. Am J Physiol Cell Physiol , 2010, 298(4):942-951.
[12]Zhou Y, Li G, Wu J, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer [J]. Tumour Biol, 2010, 31 (6): 549-558.
[13]Xiang ZL, Zeng ZC, Fan J, et al. Expression profiling of fixed tissues identified hypoxia-inducible factor-1 alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma [J]. Clin Cancer Res, 2011, 17(16): 5463-5472.
[14]Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients [J]. Cancer Biol Ther, 2006, 5(7):808-814.
[15]Suhr F, Brixius K, Bloch W. Angiogenic and vascular modulation by extracellular matrix cleavage products [J]. Curr Pharm Des, 2009, 15(4):389-410.
[16]Hassona Y, Cirillo N, Heesom K, et al. Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion [J]. Br J Cancer, 2014, 111(6):1230-1237.
[17]Wang SY, Yu L, Ling GQ, et al. Vasculogenic mimicry and its clinical significance in medulloblastoma [J]. Cancer Biol Ther, 2012, 13(5):341-348.
[18]Guttman D, Stern Y, Shpitzer T, et al. Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue [J]. Oral Oncol, 2004, 40(8):798-803.
[19]Monteiro-Amado F, Castro-Silva II, Lima CJ, et al. Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth [J]. Braz Dent J, 2013, 24(1):3-9.